SUPERNUS PHARMACEUTICALS, INC. Deferred Income Tax Liabilities, Net
SUPERNUS PHARMACEUTICALS, INC. (SUPN) had Deferred Income Tax Liabilities, Net of $0 as of 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DeferredIncomeTaxLiabilitiesNet · last filed 2026-03-02
- 2025-12-31: Deferred Income Tax Liabilities, Net $0.00.
- 2025-09-30: Deferred Income Tax Liabilities, Net $0.00.
- 2025-06-30: Deferred Income Tax Liabilities, Net $0.00.
- 2025-03-31: Deferred Income Tax Liabilities, Net $981.00K.
| Period end | Deferred Income Tax Liabilities, Net |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-02 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-05 |
| 2025-03-31 | $981.00K 10-Q · filed 2025-05-06 |
| 2024-12-31 | $4.96M 10-K · filed 2026-03-02 |
| 2024-09-30 | $7.36M 10-Q · filed 2024-11-04 |
| 2024-06-30 | $11.44M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $19.50M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $24.96M 10-K · filed 2025-02-25 |
| 2023-09-30 | $35.22M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $44.30M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $49.67M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $49.81M 10-Q · filed 2023-11-08 |
| 2022-09-30 | $58.16M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $59.31M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $62.84M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $85.36M 10-K · filed 2023-03-09 |
| 2021-09-30 | $34.15M 10-Q · filed 2021-11-05 |
| 2021-06-30 | $32.99M 10-Q · filed 2021-08-06 |
| 2021-03-31 | $31.74M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $35.22M 10-K · filed 2022-04-13 |
| 2020-09-30 | $37.94M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $35.72M 10-Q · filed 2020-08-17 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |